

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1.-23. (Canceled)

24. (Currently Amended) An oligopeptide or polypeptide comprising an amino acid sequence with ~~at least 78%~~ at least 81% identity to SEQ ID NO:14.

25. (Previously Presented) The oligopeptide or polypeptide of claim 24, which reacts with sera from individuals who are infected with the hepatitis B variant HDB 11.

26. (Currently Amended) An oligopeptide or polypeptide, comprising an amino acid sequence in which ~~from 0 to 10 amino acids~~ 0 to 9 amino acids are substituted, deleted or inserted as compared with SEQ ID NO:14.

27. (Previously Presented) The oligopeptide or polypeptide of claim 26, which reacts with sera from individuals who are infected with the hepatitis B variant HDB 11.

28. (Currently Amended) An oligopeptide or polypeptide comprising at least 5 consecutive amino acids from SEQ ID NO:12, and comprising at least one of the

amino acid positions 54, 61, 72, 73, 74, 75, 76, 78, 85, 87, and 94 of SEQ ID NO:12, or comprising at least 6 consecutive amino acids from SEQ ID NO:12, and comprising at least amino acid position 85.

29. (Previously Presented) The oligopeptide or polypeptide of claim 28, comprising an amino acid sequence chosen from the amino acid sequences of SEQ ID NO:12 to SEQ ID NO:30.

30. (Previously Presented) The oligopeptide or polypeptide of claim 28, which reacts with sera from individuals who are infected with the hepatitis B variant HDB 11.

31. (Currently Amended) {{A}}- An oligopeptide or polypeptide, comprising a length of at least 5 amino acids, and comprising at least one of the amino acid positions 96, 103, 114, 115, 116, 117, 118, 120, 127, 129, and 136 54, 61, 72, 73, 74, 75, 76, 78, 85, 87, and 94 of SEQ ID NO:12, or comprising a length of at least 6 amino acids, and comprising position 85 of SEQ ID NO:12, wherein position 96 54 is alanine, position 103 61 is isoleucine, position 114 72 is alanine, position 115 73 is isoleucine, position 116 74 is asparagine, position 117 75 is asparagine, position 118 76 is arginine, position 120 78 is glutamine, position 127 85 is threonine, position 129 87 is histidine, and position 136 94 is tyrosine.

32. (Previously Presented) The oligopeptide or polypeptide of claim 31, which reacts with sera from individuals who are infected with the hepatitis B variant HDB 11.

33. (Currently Amended) A composition comprising at least one immunogenic molecule comprising one or more oligopeptides or polypeptides as claimed in one of claims 24 to 32, and optionally further comprising one or more ~~[[H8V]]~~ HBV immunogens.

34. (Previously Presented) A method of preparing the oligopeptide or polypeptide as claimed in one of claims 24, 26, 28, 29, or 31, which comprises culturing a cell and expressing the oligopeptide or polypeptide in said cell.

35. (Previously Presented) The method as claimed in claim 34, wherein the oligopeptide or polypeptide is isolated from the cells and separated from other oligopeptides or polypeptides.

36. (Withdrawn) An antibody which binds to the oligopeptide or polypeptide as claimed in one of claims 24, 26, 28, 29, or 31.

37. (Withdrawn) The antibody as claimed in claim 36, which binds to an oligopeptide or polypeptide comprising a sequence with at least 78% identity to SEQ ID

NO:14 with higher affinity than to HBs antigens belonging to genotype D, subtype ayw2, of hepatitis B virus.

38. (Withdrawn) The antibody as claimed in claim 36, which does not bind to HBs antigens belonging to genotype D, subtype ayw2, of hepatitis B virus.

39. (Withdrawn) An antiidiotypic antibody which represents an amino acid sequence as defined in one of claims 24, 26, 28, 29, or 31.

40. (Withdrawn) A kit for detecting hepatitis B viruses, comprising at least one of

- (i) an oligopeptide or polypeptide as claimed in one of claims 24, 26, 28, 29, or 31;
- (ii) an oligonucleotide or polynucleotide encoding said oligopeptide or polypeptide; and
- (iii) an antibody which recognizes said oligopeptide or polypeptide; and

41. (Currently Amended) A method for detecting a hepatitis B antigen, comprising

- (a) incubating a sample with ~~the antibody of claim 36~~ an antibody which binds to the oligopeptide or polypeptide as claimed in one of claims 24, 26, 28, 29, or 31 under conditions which allow the formation of antigen-antibody complexes; and
- (b) detecting antigen-antibody complexes.

42. (Withdrawn) A method of identifying antibodies directed against a hepatitis B antigen, comprising

- (a) incubating a sample with an oligopeptide or polypeptide as claimed in one of claims 24, 26, 28, 29, or 31 under conditions which allow the formation of antigen-antibody complexes; and
- (b) detecting antibody-antigen complexes comprising said oligopeptide or polypeptide.